nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CHRM3—nephrolithiasis	0.876	1	CbGaD
Tolterodine—CHRM3—ureter—nephrolithiasis	0.0121	0.437	CbGeAlD
Tolterodine—CHRM4—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00708	0.124	CbGpPWpGaD
Tolterodine—CHRM5—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00678	0.119	CbGpPWpGaD
Tolterodine—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00478	0.0837	CbGpPWpGaD
Tolterodine—CHRM2—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00471	0.0826	CbGpPWpGaD
Tolterodine—CYP2C19—urine—nephrolithiasis	0.00367	0.132	CbGeAlD
Tolterodine—Fesoterodine—CHRM3—nephrolithiasis	0.0034	0.562	CrCbGaD
Tolterodine—CYP2C9—urine—nephrolithiasis	0.00284	0.102	CbGeAlD
Tolterodine—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00268	0.0808	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00233	0.0702	CcSEcCtD
Tolterodine—CYP3A4—urine—nephrolithiasis	0.00217	0.078	CbGeAlD
Tolterodine—CYP2D6—urine—nephrolithiasis	0.00213	0.0768	CbGeAlD
Tolterodine—CHRM4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00157	0.0274	CbGpPWpGaD
Tolterodine—Disopyramide—CHRM3—nephrolithiasis	0.00152	0.251	CrCbGaD
Tolterodine—CHRM5—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0015	0.0263	CbGpPWpGaD
Tolterodine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0014	0.0422	CcSEcCtD
Tolterodine—CHRM4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00132	0.0231	CbGpPWpGaD
Tolterodine—CHRM5—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00126	0.0221	CbGpPWpGaD
Tolterodine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0372	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00123	0.037	CcSEcCtD
Tolterodine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0012	0.0362	CcSEcCtD
Tolterodine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00114	0.0345	CcSEcCtD
Tolterodine—Brompheniramine—CHRM3—nephrolithiasis	0.00113	0.187	CrCbGaD
Tolterodine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.0011	0.0333	CcSEcCtD
Tolterodine—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00106	0.0185	CbGpPWpGaD
Tolterodine—CHRM2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00104	0.0183	CbGpPWpGaD
Tolterodine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00104	0.0314	CcSEcCtD
Tolterodine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00102	0.0307	CcSEcCtD
Tolterodine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000979	0.0295	CcSEcCtD
Tolterodine—CHRM3—renal system—nephrolithiasis	0.000965	0.0348	CbGeAlD
Tolterodine—CHRM4—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00096	0.0168	CbGpPWpGaD
Tolterodine—CHRM3—kidney—nephrolithiasis	0.000933	0.0336	CbGeAlD
Tolterodine—CHRM5—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000919	0.0161	CbGpPWpGaD
Tolterodine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000905	0.0273	CcSEcCtD
Tolterodine—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000887	0.0156	CbGpPWpGaD
Tolterodine—CHRM2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000876	0.0154	CbGpPWpGaD
Tolterodine—KCNH2—renal system—nephrolithiasis	0.000856	0.0308	CbGeAlD
Tolterodine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000839	0.0253	CcSEcCtD
Tolterodine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000825	0.0249	CcSEcCtD
Tolterodine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000812	0.0245	CcSEcCtD
Tolterodine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000782	0.0236	CcSEcCtD
Tolterodine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000782	0.0236	CcSEcCtD
Tolterodine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000779	0.0235	CcSEcCtD
Tolterodine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000765	0.0231	CcSEcCtD
Tolterodine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000756	0.0228	CcSEcCtD
Tolterodine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00075	0.0226	CcSEcCtD
Tolterodine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00075	0.0226	CcSEcCtD
Tolterodine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000732	0.0221	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000683	0.0206	CcSEcCtD
Tolterodine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000667	0.0201	CcSEcCtD
Tolterodine—CHRM4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000667	0.0117	CbGpPWpGaD
Tolterodine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00066	0.0199	CcSEcCtD
Tolterodine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000647	0.0113	CbGpPWpGaD
Tolterodine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000646	0.0195	CcSEcCtD
Tolterodine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000645	0.0113	CbGpPWpGaD
Tolterodine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000641	0.0193	CcSEcCtD
Tolterodine—Pain—Hydrochlorothiazide—nephrolithiasis	0.000641	0.0193	CcSEcCtD
Tolterodine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000639	0.0112	CbGpPWpGaD
Tolterodine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000618	0.0186	CcSEcCtD
Tolterodine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000613	0.0185	CcSEcCtD
Tolterodine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000593	0.0179	CcSEcCtD
Tolterodine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000552	0.0167	CcSEcCtD
Tolterodine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000538	0.0162	CcSEcCtD
Tolterodine—CYP3A4—renal system—nephrolithiasis	0.00053	0.0191	CbGeAlD
Tolterodine—CYP2D6—renal system—nephrolithiasis	0.000522	0.0188	CbGeAlD
Tolterodine—CHRM5—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000518	0.00907	CbGpPWpGaD
Tolterodine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000513	0.0155	CcSEcCtD
Tolterodine—CYP3A4—kidney—nephrolithiasis	0.000513	0.0185	CbGeAlD
Tolterodine—CYP2D6—kidney—nephrolithiasis	0.000505	0.0182	CbGeAlD
Tolterodine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000496	0.015	CcSEcCtD
Tolterodine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00047	0.0142	CcSEcCtD
Tolterodine—CHRM4—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000469	0.00822	CbGpPWpGaD
Tolterodine—CHRM4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000469	0.00822	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000463	0.00812	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.000463	0.00811	CbGpPWpGaD
Tolterodine—CHRM5—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000449	0.00787	CbGpPWpGaD
Tolterodine—CHRM5—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000449	0.00787	CbGpPWpGaD
Tolterodine—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000444	0.00778	CbGpPWpGaD
Tolterodine—CHRM5—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000374	0.00656	CbGpPWpGaD
Tolterodine—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000364	0.00639	CbGpPWpGaD
Tolterodine—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000363	0.00637	CbGpPWpGaD
Tolterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000335	0.00587	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000326	0.00571	CbGpPWpGaD
Tolterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000325	0.0057	CbGpPWpGaD
Tolterodine—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000316	0.00554	CbGpPWpGaD
Tolterodine—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000316	0.00554	CbGpPWpGaD
Tolterodine—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000312	0.00547	CbGpPWpGaD
Tolterodine—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000312	0.00547	CbGpPWpGaD
Tolterodine—CHRM4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000302	0.0053	CbGpPWpGaD
Tolterodine—CHRM5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000289	0.00507	CbGpPWpGaD
Tolterodine—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000283	0.00497	CbGpPWpGaD
Tolterodine—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000263	0.00462	CbGpPWpGaD
Tolterodine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000261	0.00457	CbGpPWpGaD
Tolterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000259	0.00454	CbGpPWpGaD
Tolterodine—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000258	0.00453	CbGpPWpGaD
Tolterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000248	0.00434	CbGpPWpGaD
Tolterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000236	0.00413	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000228	0.004	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—RGS14—nephrolithiasis	0.000218	0.00383	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—RGS14—nephrolithiasis	0.000207	0.00363	CbGpPWpGaD
Tolterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000204	0.00357	CbGpPWpGaD
Tolterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000201	0.00352	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—RGS14—nephrolithiasis	0.000198	0.00348	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000197	0.00345	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000189	0.00331	CbGpPWpGaD
Tolterodine—CHRM4—GPCR ligand binding—PTH—nephrolithiasis	0.00018	0.00316	CbGpPWpGaD
Tolterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000175	0.00306	CbGpPWpGaD
Tolterodine—CHRM5—GPCR ligand binding—PTH—nephrolithiasis	0.000173	0.00303	CbGpPWpGaD
Tolterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000172	0.00302	CbGpPWpGaD
Tolterodine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00017	0.00299	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—DGKH—nephrolithiasis	0.000154	0.0027	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000154	0.0027	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000153	0.00269	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000152	0.00266	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000148	0.00259	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ADCY10—nephrolithiasis	0.000144	0.00252	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—DGKH—nephrolithiasis	0.00014	0.00245	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.00014	0.00245	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000139	0.00244	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000138	0.00242	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ADCY10—nephrolithiasis	0.000138	0.00242	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—DGKH—nephrolithiasis	0.000134	0.00235	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000133	0.00233	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000131	0.0023	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—RGS14—nephrolithiasis	0.000122	0.00214	CbGpPWpGaD
Tolterodine—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000122	0.00213	CbGpPWpGaD
Tolterodine—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	0.000121	0.00212	CbGpPWpGaD
Tolterodine—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	0.00012	0.0021	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—RGS14—nephrolithiasis	0.000117	0.00205	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000111	0.00195	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000107	0.00187	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000104	0.00182	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	0.000104	0.00182	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000103	0.0018	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—PTH—nephrolithiasis	0.000102	0.00179	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—CHRM3—nephrolithiasis	0.000101	0.00177	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—GRHPR—nephrolithiasis	9.83e-05	0.00172	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—PTH—nephrolithiasis	9.75e-05	0.00171	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	9.7e-05	0.0017	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—CHRM3—nephrolithiasis	9.69e-05	0.0017	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	9.67e-05	0.0017	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	9.58e-05	0.00168	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	9.43e-05	0.00165	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	9.4e-05	0.00165	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	9.31e-05	0.00163	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—PTH—nephrolithiasis	9.25e-05	0.00162	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—PTH—nephrolithiasis	8.86e-05	0.00155	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AGXT—nephrolithiasis	8.76e-05	0.00154	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—DGKH—nephrolithiasis	8.26e-05	0.00145	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.26e-05	0.00145	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	8.25e-05	0.00145	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	8.22e-05	0.00144	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	8.14e-05	0.00143	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—DGKH—nephrolithiasis	7.91e-05	0.00139	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ATP6V0A4—nephrolithiasis	7.91e-05	0.00139	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	7.51e-05	0.00132	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—SLC26A1—nephrolithiasis	7.45e-05	0.00131	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—APRT—nephrolithiasis	7.45e-05	0.00131	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	7.41e-05	0.0013	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	6.87e-05	0.0012	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	6.85e-05	0.0012	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	6.82e-05	0.0012	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	6.78e-05	0.00119	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	6.73e-05	0.00118	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GRHPR—nephrolithiasis	6.39e-05	0.00112	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	6.24e-05	0.00109	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	6.22e-05	0.00109	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	6.16e-05	0.00108	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CHRM3—nephrolithiasis	5.97e-05	0.00105	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	5.88e-05	0.00103	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GRHPR—nephrolithiasis	5.83e-05	0.00102	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CHRM3—nephrolithiasis	5.72e-05	0.001	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AGXT—nephrolithiasis	5.7e-05	0.000999	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	5.57e-05	0.000977	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.57e-05	0.000977	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	5.55e-05	0.000974	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.55e-05	0.000974	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	5.5e-05	0.000964	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.5e-05	0.000964	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTH—nephrolithiasis	5.46e-05	0.000958	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AQP1—nephrolithiasis	5.31e-05	0.000931	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AGXT—nephrolithiasis	5.24e-05	0.000919	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTH—nephrolithiasis	5.23e-05	0.000917	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AGXT—nephrolithiasis	5.2e-05	0.000911	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APRT—nephrolithiasis	4.84e-05	0.000849	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	4.84e-05	0.000849	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	4.46e-05	0.000781	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APRT—nephrolithiasis	4.46e-05	0.000781	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APRT—nephrolithiasis	4.42e-05	0.000774	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	4.42e-05	0.000774	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	4.03e-05	0.000706	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	3.98e-05	0.000697	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	3.84e-05	0.000674	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTH—nephrolithiasis	3.68e-05	0.000646	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTH—nephrolithiasis	3.67e-05	0.000644	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTH—nephrolithiasis	3.64e-05	0.000638	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AQP1—nephrolithiasis	3.45e-05	0.000605	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AGXT—nephrolithiasis	3.43e-05	0.000601	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AQP1—nephrolithiasis	3.18e-05	0.000557	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AQP1—nephrolithiasis	3.15e-05	0.000552	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CHRM3—nephrolithiasis	3.12e-05	0.000547	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	2.91e-05	0.000511	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APRT—nephrolithiasis	2.91e-05	0.000511	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	2.87e-05	0.000503	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CHRM3—nephrolithiasis	2.85e-05	0.000499	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SPP1—nephrolithiasis	2.74e-05	0.000481	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SPP1—nephrolithiasis	2.63e-05	0.000461	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AQP1—nephrolithiasis	2.08e-05	0.000364	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	1.88e-05	0.000329	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	1.85e-05	0.000324	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	1.84e-05	0.000323	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	1.83e-05	0.00032	CbGpPWpGaD
